On August 29, 2021 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, reported that it will have multiple scientific data presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2021, held on September 16-21 (Press release, Innovent Biologics, AUG 29, 2021, View Source [SID1234586981]). These presentations include the data from Phase 3 trials of sintilimab in esophageal squamous cell carcinoma and gastric cancer which are disclosed for the first time, as well as results from studies of IBI310 (an anti-CTLA-4 monoclonal antibody) and pemigatinib1 (IBI375, an FGFR1/2/3 inhibitor).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of Innovent’s ESMO (Free ESMO Whitepaper) Congress 2021 presentations are as follows:
Cancer Type: Oesophagogastric Cancer
Topic: Sintilimab plus chemotherapy compared to placebo plus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First Results of the Phase 3 ORIENT-15 Study
Presentation Type: Mini Oral
Abstract Number: LBA52
Researcher: Professor Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
Cancer Type: Gastric Cancer
Topic: Sintilimab plus chemotherapy compared to placebo plus chemotherapy as first-line therapy for patients with unresectable or metastatic gastric or gastroesophageal adenocarcinoma: First Results of the Phase 3 ORIENT-16 Study
Presentation Type: Mini Oral
Abstract Number: LBA53
Researcher: Professor Jianming Xu, Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital
Cancer Type: Melanoma
Topic: IBI310 alone or in combination with sintilimab for advanced melanoma: updated results of a Phase 1 study
Presentation Type: e-Poster
Abstract Number: 1516
Researcher: Professor Jun Guo, Peking University Cancer Hospital & Institute, Beijing, China
Cancer Type: Cholangiocarcinoma
Topic: FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
Presentation Type: e-Poster
Abstract Number: 2064
Researcher: Professor Jian Zhou, Zhongshan Hospital, Fudan University, Shanghai, China
Cancer Type: Cholangiocarcinoma
Topic: Efficacy and safety of pemigatinib in Chinese patients with unresectable, advanced/ recurrent or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement that failed to prior systemic therapy
Presentation Type: e-Poster
Abstract Number: 1810
Researcher: Professor Jian Zhou, Zhongshan Hospital, Fudan University, Shanghai, China